Results from the phase 3 CLL17 trial (NCT04608318) are helping clarify the ongoing debate over continuous vs fixed-duration therapy in frontline chronic lymphocytic leukemia (CLL) ...

Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children ...

The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...

Curis, a biotechnology company dedicated to delivering innovative cancer treatments, has made significant strides in its mission to improve the lives of patients with lymphoma and leukemia. In their ...

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of blood cancers such as Chronic Lymphocytic Leukemia The post Women’s Health ...

Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns ...

Size-exclusion chromatography (SEC) was used to purify extracellular vesicles (EVs) from the plasma of chronic myeloid leukemia (CML) patients to evaluate treatment responses and mutation statuses.

Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Zia Sherrell is a health journalist, copywriter, and freelance writing mentor with over 1 million published words across major publications, including Healthline, Medical News Today, Business Insider, ...